Predictors of secondary HIV transmission risk in a cohort of adolescents living with HIV in South Africa.

"Conflicts of interest The project has been funded by the International AIDS Society through the CIPHER grant (155-Hod; 2018/625-TOS). The views expressed in written materials or publications do not necessarily reflect the official policies of the International AIDS society; the Claude Leon Foundation [F08 559/C]; Evidence for HIV Prevention in Southern Africa (EHPSA), a UK aid programme managed by Mott MacDonald; Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; Nuffield Foundation, but the views expressed are those of the authors and not necessarily the Foundation (Visit www.nuffieldfoundation.org); the Oak Foundation grants [R46194/AA001] and [OFIL-20–057]; the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA); the John Fell Funds [161/033] and [103/757]; the Leverhulme Trust (PLP-2014–095); University of Oxford's ESRC Impact Acceleration Account (IAA) [1602-KEA-189] and [K1311-KEA-004]; UNICEF Eastern and Southern Africa Office (UNICEF-ESARO); UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1). E.T. was supported by the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Funding was also provided for the research team by the European Research Council (ERC) under the European Union's Seventh Framework Programme [FP7/2007-2013]/ ERC grant agreement no. 313421, the European Union's Horizon 2020 research and innovation programme/ERC grant agreement no. 737476). E.T. was supported by the Oxford University Clarendon-Green Templeton College Scholarship in 2012-2016. The views expressed in written materials or publications do not necessarily reflect the official policies of the International AIDS society; the Claude Leon Foundation [F08 559/C]; Evidence for HIV Prevention in Southern Africa (EHPSA), a UK aid programme managed by Mott MacDonald; Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; Nuffield Foundation, but the views expressed are those of the authors and not necessarily the Foundation. Visit www.nuffieldfoundation.org; the Oak Foundation grants [R46194/AA001] and [OFIL-20–057]; the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA); the John Fell Funds [161/033] and [103/757]; the Leverhulme Trust (PLP-2014–095); University of Oxford's ESRC Impact Acceleration Account (IAA) [1602-KEA-189] and [K1311-KEA-004]; UNICEF Eastern and Southern Africa Office (UNICEF-ESARO); UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1). Research reported in this publication was supported by the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health."

"Conflicts of interestThe project has been funded by the International AIDS Society through the CIPHER grant (155-Hod; 2018/625-TOS). The views expressed in written materials or publications do not necessarily reflect the official policies of the International AIDS society; the Claude Leon Foundation [F08 559/C]; Evidence for HIV Prevention in Southern Africa (EHPSA), a UK aid programme managed by Mott MacDonald; Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; Nuffield Foundation, but the views expressed are those of the authors and not necessarily the Foundation (Visit www.nuffieldfoundation.org); the Oak Foundation grants [R46194/AA001] and [OFIL-20–057]; the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA); the John Fell Funds [161/033] and [103/757]; the Leverhulme Trust (PLP-2014–095); University of Oxford's ESRC Impact Acceleration Account (IAA) [1602-KEA-189] and [K1311-KEA-004]; UNICEF Eastern and Southern Africa Office (UNICEF-ESARO); UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1). E.T. was supported by the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Funding was also provided for the research team by the European Research Council (ERC) under the European Union's Seventh Framework Programme [FP7/2007-2013]/ ERC grant agreement no. 313421, the European Union's Horizon 2020 research and innovation programme/ERC grant agreement no. 737476). E.T. was supported by the Oxford University Clarendon-Green Templeton College Scholarship in 2012-2016.The views expressed in written materials or publications do not necessarily reflect the official policies of the International AIDS society; the Claude Leon Foundation [F08 559/C]; Evidence for HIV Prevention in Southern Africa (EHPSA), a UK aid programme managed by Mott MacDonald; Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; Nuffield Foundation, but the views expressed are those of the authors and not necessarily the Foundation. Visit www.nuffieldfoundation.org; the Oak Foundation grants [R46194/AA001] and [OFIL-20–057]; the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA); the John Fell Funds [161/033] and [103/757]; the Leverhulme Trust (PLP-2014–095); University of Oxford's ESRC Impact Acceleration Account (IAA) [1602-KEA-189] and [K1311-KEA-004]; UNICEF Eastern and Southern Africa Office (UNICEF-ESARO); UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1). Research reported in this publication was supported by the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. The project has been funded by the International AIDS Society through the CIPHER grant (155-Hod; 2018/625-TOS). The views expressed in written materials or publications do not necessarily reflect the official policies of the International AIDS society; the Claude Leon Foundation [F08 559/C]; Evidence for HIV Prevention in Southern Africa (EHPSA), a UK aid programme managed by Mott MacDonald; Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; Nuffield Foundation, but the views expressed are those of the authors and not necessarily the Foundation (Visit www.nuffieldfoundation.org); the Oak Foundation grants [R46194/AA001] and [OFIL-20–057]; the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA); the John Fell Funds [161/033] and [103/757]; the Leverhulme Trust (PLP-2014–095); University of Oxford's ESRC Impact Acceleration Account (IAA) [1602-KEA-189] and [K1311-KEA-004]; UNICEF Eastern and Southern Africa Office (UNICEF-ESARO); UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1). E.T. was supported by the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Funding was also provided for the research team by the European Research Council (ERC) under the European Union's Seventh Framework Programme [FP7/2007-2013]/ ERC grant agreement no. 313421, the European Union's Horizon 2020 research and innovation programme/ERC grant agreement no. 737476). E.T. was supported by the Oxford University Clarendon-Green Templeton College Scholarship in 2012-2016. The views expressed in written materials or publications do not necessarily reflect the official policies of the International AIDS society; the Claude Leon Foundation [F08 559/C]; Evidence for HIV Prevention in Southern Africa (EHPSA), a UK aid programme managed by Mott MacDonald; Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; Nuffield Foundation, but the views expressed are those of the authors and not necessarily the Foundation. Visit www.nuffieldfoundation.org; the Oak Foundation grants [R46194/AA001] and [OFIL-20–057]; the Regional Inter-Agency Task Team for Children Affected by AIDS - Eastern and Southern Africa (RIATT-ESA); the John Fell Funds [161/033] and [103/757]; the Leverhulme Trust (PLP-2014–095); University of Oxford's ESRC Impact Acceleration Account (IAA) [1602-KEA-189] and [K1311-KEA-004]; UNICEF Eastern and Southern Africa Office (UNICEF-ESARO); UKRI GCRF Accelerating Achievement for Africa's Adolescents (Accelerate) Hub (Grant Ref: ES/S008101/1). Research reported in this publication was supported by the Fogarty International Center, National Institute on Mental Health, National Institutes of Health under Award Number K43TW011434. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health."